Clinical Trial Update: Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pharmacokinetics, efficacy, tolerability, and safety of subcutaneous Newnorm immunoglobulin in patients with primary immune deficiencie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Deficiency

Drugs mentioned

• Newnorm (human immunoglobulin)

Snippet

Sponsor: Octapharma | Conditions: Primary Immune Deficiency | Phase 3 | Status: ACTIVE_NOT_RECRUITING